Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06741644 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by CStone Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 660
- Enrollment target
NCT06741644: Recruiting Phase 1 study, sponsored by CStone Pharmaceuticals.
NCT06741644 is a Phase 1 study that is actively recruiting participants, run by CStone Pharmaceuticals. The registered enrollment target is 660 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1000% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06741644, a Phase 1 study, is actively recruiting participants, sponsored by CStone Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 660 participants
- Enrollment target
Study Summary
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.
Primary Outcome
Participants will receive CS2009 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT).
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG CS2009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2025-02-24 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What NCT06741644 shows while recruiting
NCT06741644 is an interventional study that assigns participants to a tested intervention. The registered 660 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1000% higher).
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT06741644 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06741644 about?
NCT06741644 is a clinical study titled "A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors". This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a ...
What is the current status of trial NCT06741644?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 660 participants. The study started on 2025-02-24. Estimated completion is 2028-01.
What interventions are being tested in trial NCT06741644?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), CS2009 (DRUG).
Who is sponsoring clinical trial NCT06741644?
This trial is sponsored by CStone Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06741644's enrollment target sits among peer trials
660 22nd of 2000 higher than 1,979 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- NCT03346694 · 660 participants · NA
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
- NCT05407636 · 660 participants · Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
- NCT05470205 · 660 participants · Phase 3
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI